Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Obstet Gynecol. Nov 10, 2013; 2(4): 167-175
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.167
Published online Nov 10, 2013. doi: 10.5317/wjog.v2.i4.167
Cytoreductive surgery and HIPEC after neoadjuvant chemotherapy for advanced epithelial ovarian cancer
Marco Lotti, Luca Campanati, Federico Coccolini, Michele Pisano, Elia Poiasina, Diego Rossetti, Paolo Bertoli, Luca Ansaloni, Unit of General Surgery 1, Papa Giovanni XXIII Hospital, 24128 Bergamo, Italy
Luisa Maria Busci, Giuseppe Grosso, Diego Rossetti, Luigi Frigerio, Unit of Gynecology and Obstetrics, Papa Giovanni XXIII Hospital, 24128 Bergamo, Italy
Fausto Catena, Giorgio Ercolani, Antonio Daniele Pinna, Unit of General Surgery, St.Orsola-Malpighi University Hospital, 40138 Bologna, Italy
Naoual Bakrin, Department of Gynecology, Lyon Sud Hospital, 69310 Pierre Benite, France
Pierandrea De Iaco, Martina Rossi, Unit of Gynecology and Obstetrics, St.Orsola-Malpighi University Hospital, V40138 Bologna, Italy
Claudio Zamagni, Medical Oncology, St.Orsola-Malpighi University Hospital, 40138 Bologna, Italy
Author contributions: Lotti M and Ansaloni L designed the study protocol and wrote the article; Busci LM, Catena F, Campanati L, Coccolini F, Bakrin N, De Iaco P, Ercolani G, Grosso G, Pisano M, Poiasina E, Rossetti D, Rossi M, Zamagni C, Bertoli P, Pinna AD and Frigerio L were involved in patients’ recruitment, treatment and in providing data for analysis.
Correspondence to: Dr. Luca Ansaloni, MD, Unit of General Surgery 1, Papa Giovanni XXIII Hospital, Piazza OMS, Organizzazione mondiale della sanità 1, 24128 Bergamo, Italy. lansaloni@hpg23.it
Telephone: +39-3-5269310 Fax: +39-3-5266898
Received: February 21, 2013
Revised: April 23, 2013
Accepted: July 9, 2013
Published online: November 10, 2013
Revised: April 23, 2013
Accepted: July 9, 2013
Published online: November 10, 2013
Core Tip
Core tip: This is a report of a phase 2 prospective observational study, which served as a pilot study for the CHORINE trial protocol (http://www.chorine.org). Our pilot study supports the feasibility of neoadjuvant chemotherapy (NACT) followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for upfront treatment of advanced epithelial ovarian cancer. This combined therapy does not reduce the possibility to start the postoperative systemic chemotherapy in an acceptable period of time. We believe that in the upfront setting NACT can better select chemoresponsive patients, increasing their chance to take advantage from HIPEC, reducing the surgical stress and the perioperative complications.